Sam Brusco, Associate Editor07.14.23
CurvaFix, a developer of devices to repair fractures in curved bones, revealed that Mark Foster, previously president and CEO of minimally invasive orthopedic procedure firm Trice Medical, was named CEO.
Foster succeeds founder and current CEO Steve Dimmer, who will remain in a strategic advisory role. Before Trice Medical, he was VP of Sports Medicine Business for Smith+Nephew and also served in leadership roles at Boston Scientific.
“I have had the opportunity to observe the successful implementation and adoption of CurvaFix IM Implants in the orthopedic pelvic fracture fixation market, for which Steve has played a pivotal role in taking the company to this point,” Foster told the press. “I am looking forward to leading the CurvaFix team in scaling CurvaFix’s technology to benefit many more patients, physicians, and payers.”
The company also revealed it has closed $39 million in equity financing, led by MVM Partners and assisted by Sectoral Asset Management and other investors. The company said the $39 million proceeds will be used to expand treatment for fragility fractures of the pelvis (FFP) in the U.S. by supporting commercialization of the CurvaFix IM (intramedullary) implant.
“CurvaFix's ability to benefit patients, physicians, and health systems, while simultaneously addressing the undertreated FFP segment makes CurvaFix a rare asset in the crowded world of orthopedics,” said Eric Fritz, MVM Partner. “We are thrilled to be involved and look forward to supporting the company’s next phase of growth.”
The company launched its 7.5 mm CurvaFix IM implant for small-boned patients in February 2023.
Foster succeeds founder and current CEO Steve Dimmer, who will remain in a strategic advisory role. Before Trice Medical, he was VP of Sports Medicine Business for Smith+Nephew and also served in leadership roles at Boston Scientific.
“I have had the opportunity to observe the successful implementation and adoption of CurvaFix IM Implants in the orthopedic pelvic fracture fixation market, for which Steve has played a pivotal role in taking the company to this point,” Foster told the press. “I am looking forward to leading the CurvaFix team in scaling CurvaFix’s technology to benefit many more patients, physicians, and payers.”
The company also revealed it has closed $39 million in equity financing, led by MVM Partners and assisted by Sectoral Asset Management and other investors. The company said the $39 million proceeds will be used to expand treatment for fragility fractures of the pelvis (FFP) in the U.S. by supporting commercialization of the CurvaFix IM (intramedullary) implant.
“CurvaFix's ability to benefit patients, physicians, and health systems, while simultaneously addressing the undertreated FFP segment makes CurvaFix a rare asset in the crowded world of orthopedics,” said Eric Fritz, MVM Partner. “We are thrilled to be involved and look forward to supporting the company’s next phase of growth.”
The company launched its 7.5 mm CurvaFix IM implant for small-boned patients in February 2023.